Literature DB >> 12145742

Neuregulin 1 and susceptibility to schizophrenia.

Hreinn Stefansson1, Engilbert Sigurdsson, Valgerdur Steinthorsdottir, Soley Bjornsdottir, Thordur Sigmundsson, Shyamali Ghosh, Jon Brynjolfsson, Steinunn Gunnarsdottir, Omar Ivarsson, Thomas T Chou, Omar Hjaltason, Birgitta Birgisdottir, Helgi Jonsson, Vala G Gudnadottir, Elsa Gudmundsdottir, Asgeir Bjornsson, Brynjolfur Ingvarsson, Andres Ingason, Sigmundur Sigfusson, Hronn Hardardottir, Richard P Harvey, Donna Lai, Mingdong Zhou, Daniela Brunner, Vincent Mutel, Acuna Gonzalo, Greg Lemke, Jesus Sainz, Gardar Johannesson, Thorkell Andresson, Daniel Gudbjartsson, Andrei Manolescu, Michael L Frigge, Mark E Gurney, Augustine Kong, Jeffrey R Gulcher, Hannes Petursson, Kari Stefansson.   

Abstract

The cause of schizophrenia is unknown, but it has a significant genetic component. Pharmacologic studies, studies of gene expression in man, and studies of mouse mutants suggest involvement of glutamate and dopamine neurotransmitter systems. However, so far, strong association has not been found between schizophrenia and variants of the genes encoding components of these systems. Here, we report the results of a genomewide scan of schizophrenia families in Iceland; these results support previous work, done in five populations, showing that schizophrenia maps to chromosome 8p. Extensive fine-mapping of the 8p locus and haplotype-association analysis, supplemented by a transmission/disequilibrium test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia. NRG1 is expressed at central nervous system synapses and has a clear role in the expression and activation of neurotransmitter receptors, including glutamate receptors. Mutant mice heterozygous for either NRG1 or its receptor, ErbB4, show a behavioral phenotype that overlaps with mouse models for schizophrenia. Furthermore, NRG1 hypomorphs have fewer functional NMDA receptors than wild-type mice. We also demonstrate that the behavioral phenotypes of the NRG1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used to treat schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145742      PMCID: PMC378543          DOI: 10.1086/342734

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  54 in total

1.  Transmission/disequilibrium tests for extended marker haplotypes.

Authors:  D Clayton; H Jones
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

2.  Allegro, a new computer program for multipoint linkage analysis.

Authors:  D F Gudbjartsson; K Jonasson; M L Frigge; A Kong
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

3.  Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23.

Authors:  H M Gurling; G Kalsi; J Brynjolfson; T Sigmundsson; R Sherrington; B S Mankoo; T Read; P Murphy; E Blaveri; A McQuillin; H Petursson; D Curtis
Journal:  Am J Hum Genet       Date:  2001-03       Impact factor: 11.025

4.  Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia.

Authors:  X M Gao; K Sakai; R C Roberts; R R Conley; B Dean; C A Tamminga
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

5.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

6.  Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.

Authors:  H M Ibrahim; A J Hogg; D J Healy; V Haroutunian; K L Davis; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  2000-11       Impact factor: 18.112

7.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.

Authors:  C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus.

Authors:  Y Horikawa; N Oda; N J Cox; X Li; M Orho-Melander; M Hara; Y Hinokio; T H Lindner; H Mashima; P E Schwarz; L del Bosque-Plata; Y Horikawa; Y Oda; I Yoshiuchi; S Colilla; K S Polonsky; S Wei; P Concannon; N Iwasaki; J Schulze; L J Baier; C Bogardus; L Groop; E Boerwinkle; C L Hanis; G I Bell
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

9.  Linkage of familial schizophrenia to chromosome 13q32.

Authors:  L M Brzustowicz; W G Honer; E W Chow; D Little; J Hogan; K Hodgkinson; A S Bassett
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

10.  Protection of privacy by third-party encryption in genetic research in Iceland.

Authors:  J R Gulcher; K Kristjánsson; H Gudbjartsson; K Stefánsson
Journal:  Eur J Hum Genet       Date:  2000-10       Impact factor: 4.246

View more
  542 in total

Review 1.  Linkage and association studies of schizophrenia.

Authors:  Peter McGuffin; Kopal Tandon; Alejandro Corsico
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

2.  Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Authors:  Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-10

3.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

4.  Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression.

Authors:  Erkang Fei; Xiaochuan Ma; Cuiqing Zhu; Ting Xue; Jie Yan; Yuxia Xu; Jiangning Zhou; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

Review 5.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

Review 6.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

7.  A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.

Authors:  Vinita Jagannath; Miriam Gerstenberg; Christoph U Correll; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

8.  Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1.

Authors:  Nevena V Radonjić; Igor Jakovcevski; Vladimir Bumbaširević; Nataša D Petronijević
Journal:  Psychopharmacology (Berl)       Date:  2013-02-05       Impact factor: 4.530

Review 9.  The genetics of schizophrenia and bipolar disorder: dissecting psychosis.

Authors:  N Craddock; M C O'Donovan; M J Owen
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

10.  Neuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortex.

Authors:  Ralf S Schmid; Barbara McGrath; Bridget E Berechid; Becky Boyles; Mark Marchionni; Nenad Sestan; Eva S Anton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.